Category: 908267-63-0

On February 5, 2004, Kwan, Tricia Ann; Lagreca, Susan Deborah; Lippa, Blaise Scott; Morris, Joel; Wessel, Matthew David published a patent.Formula: C8H10BrN The title of the patent was Preparation of isothiazole derivatives as anticancer agents. And the patent contained the following:

The title compounds I [X = O or S; R1 = (substituted)heterocyclic aromatic ring; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, etc.] were prepared Compounds I are useful as as anticancer agents (no data). Thus, reaction of 3-methanesulfonyl-5-(pyridin-4-ylamino)-isothiazole-4-carboxylic acid amide (preparation given) with (4-chlorophenyl)-methanethiol yielded compound II. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Formula: C8H10BrN

The Article related to isothiazole derivative preparation anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Formula: C8H10BrN

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 11, 2014, Wang, Shaomeng; Ran, Xu; Zhao, Yujun; Yang, Chao-Yie; Liu, Liu; Bai, Longchuan; McEachern, Donna; Stuckey, Jeanne; Meagher, Jennifer Lynn; Sun, Duxin; Li, Xiaoqin; Zhou, Bing; Karatas, Hacer; Luo, Ruijuan; Chinnaiyan, Arul; Asangani, Irfan A. published a patent.Quality Control of 4-Bromo-2-isopropylpyridine The title of the patent was Preparation of pyridoindole, pyridazinoindole and pyrimidinoindole compounds as BET bromodomain inhibitors. And the patent contained the following:

The title compounds I [X = NRa, O or S; Y1, Y3 = CH or N; Y2 = CH, CRa (wherein Ra = H, alkyl, benzyl), or absent; Z = H, II (wherein B = (un)substituted aryl, heteroaryl, heterocycloalkyl, etc.; Rb = alkyl, halo, aryl, etc.; n = 0-3), G(L)C(Rc)3 (G = N, O, or S; L = absent, H, C(Rd)3; Rc, Rd = H, alkyl, (un)substituted aryl, etc.), halo, OH, or absent; A = (un)substituted 5-membered heterocyclyl; R1 = H, halo, OH, etc.] that are inhibitors of BET bromodomains useful in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, were prepared E.g., a multi-step synthesis of III, starting from 4-hydroxypyridin-2(1H)-one, was described. The ability of exemplified compounds I to bind to BET bromodomain proteins was evaluated (data given for representative compounds I). Pharmaceutical compositions comprising compound I, alone or in combination with second therapeutic agent, surgery and radiation, were disclosed. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Quality Control of 4-Bromo-2-isopropylpyridine

The Article related to pyridoindole pyridazinoindole pyrimidinoindole preparation bet bromodomain inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Quality Control of 4-Bromo-2-isopropylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 11, 2018, Crowley, Brendan M.; Bell, Ian M.; Harvey, Andrew John; Campbell, Brian T.; Greshock, Thomas J.; Rada, Vanessa L. published a patent.Product Details of 908267-63-0 The title of the patent was Preparation of substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors. And the patent contained the following:

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer’s disease, Parkinson’s disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. Compounds of formula I wherein X is SONH2 and derivatives, OSONH2 and derivatives, SO2H and SO2-C1-4 alkyl; Y is from 1 to 4 substituents and each are independently H, (un)substituted C1-4 alkyl, halo and OH; A is substituted 6-membered aryl and heteroaryl; R3 and R4 are independently H, halo and (un)substituted C1-4 alkyl; R3R4 can be taken together to form (un)substituted cyclopropyl, (un)substituted cyclobutyl, (un)substituted cyclopentyl and (un)substituted cyclohexyl; R5 and R6 are independently H and C1-4 alkyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cyclization of (1R,3R)-2,2-dimethyl-3-(4-sulfamoylphenyl)cyclopropanecarboximidamide with 3-(dimethylamino)-1-[5-(trifluoromethyl)pyridin-3-yl]prop-2-en-1-one. The invention compounds were evaluated for their α7 nAChR modulatory activity (some data given). The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Product Details of 908267-63-0

The Article related to heteroaryl phenylcyclopropane preparation nicotinic acetylcholine receptor modulator allosteric modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Product Details of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 30, 2021, Zhou, Enxing; Liu, Yuan; Wang, Hanping; Wang, Jing; Shao, Ning; Wu, Guanglong published a patent.Recommanded Product: 908267-63-0 The title of the patent was Preparation of heteroaryl compounds as casein kinase inhibitors. And the patent contained the following:

The title compounds with general formula I [wherein R1 = halogen; n = 0-2, X = independently C or N; R2 = absent or O; R3 = absent or CN; A = absent, a 4- to 7- membered (un)substituted cycloalkyl, heterocycloalkyl, a 5- to 6- membered (un)substituted heteroaryl, etc.; ring B = a 4- to 7-membered (un)substituted cycloalkyl, heterocycloalkyl, or a 5- to 6-membered (un)substituted heteroaryl, wherein up to 2 carbon atoms are replaced with a heteroatom selected from =N- or -O-] or pharmaceutically acceptable salts thereof were prepared novel casein kinase inhibitors. For example, compound II was prepared in a multi-step synthesis. Corresponding pharmaceutical compositions were also disclosed for the treatment of mood disorder, depression, bipolar disorder, solid tumor, blood cancer, lymphoma, breast cancer, melanoma, leukemia, liver cancer, and brain cancer. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Recommanded Product: 908267-63-0

The Article related to preparation heteroaryl pyrazolopyrazine pyrimidine imidazopyrazine furopyridine, human casein kinase inhibitor treatment mood disorder cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 27, 2007, Arnold, James; Berg, Stefan; Chessari, Gianni; Congreve, Miles; Edwards, Phil; Holenz, Joerg; Kers, Annika; Kolmodin, Karin; Murray, Christopher; Patel, Sahil; Rakos, Laszlo; Rotticci, Didier; Sylvester, Mark; Oehberg, Liselotte published a patent.Computed Properties of 908267-63-0 The title of the patent was Substituted isoindoles as BACE inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cognitive impairment, Alzheimers disease, neurodegeneration and dementia. And the patent contained the following:

This invention relates to compounds having the structural formula I and to their pharmaceutically acceptable salt, compositions and methods of use. These compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer disease, neurodegeneration and dementia. Compounds of formula I wherein R1 is H, NO2, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl;, CONH-C1-6 alkyl, etc.; R2 is Me, (un)substituted C0-3 alkyl-C3-6 cycloalkyl, NO2, CN, substituted C2-4 alkenyl, etc.; R3 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, etc.; m is 0, 1, 2, and 3; and their pharmaceutically acceptable salts, solvates, salts of solvates thereof are claimed. Example compound II•TFA was prepared by Suzuki cross-coupling of [3-(3-bromo-4-hydroxyphenyl)-3-(4-methoxyphenyl)-3H-isoindol-1-yl]carbamic acid tert-Bu ester with 3-methoxyphenylboronic acid; the resulting [3-(6-hydroxy-3′-methoxybiphenyl-3-yl)-3-(4-methoxyphenyl)-3H-isoindol-1-yl]carbamic acid tert-Bu ester underwent hydrolysis to give compound II•TFA. All the invention compounds were evaluated for their BACE inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 67 nM. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Computed Properties of 908267-63-0

The Article related to substituted isoindole preparation bace inhibitor, treatment alzheimer disease neurodegeneration dementia cognitive impairment isoindole preparation, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Computed Properties of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 30, 2021, Zhou, Enxing; Liu, Yuan; Wang, Hanping; Wang, Jing; Shao, Ning; Wu, Guanglong published a patent.Product Details of 908267-63-0 The title of the patent was Preparation of heteroaromatics and their methods for inhibiting casein kinases. And the patent contained the following:

The disclosure provides methods for inhibiting CK1 delta or CK1 epsilon activity, comprising administering an effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof. Compounds of formula I wherein Ar1 is (un)substituted aryl; X1, X2 and X3 are independently C and N; R7 is absent and CN; ring A is absent, X1:CR2 and R3X1:CR2, 4- to 7-membered cycloalkyl, heterocycloalkyl, etc.; R2 is NH2, CN, carboxy, azido, etc.; R3 is halo and CN; ring B is absent, X2CR5, R6X2CH and R6X2CR5, 4- to 7-membered cycloalkyl, etc.; R5 is CO2-C1-6 alkyl, COR10, azido, amido, etc.; R10 is 4- to 7-membered cycloalkyl, heterocycloalkyl and 5- to 6-membered heteroaryl; R6 is C1-6 alkyl, azido, amido, aryl, etc.; dashed bonds are single and double bonds; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their casein kinase inhibitory activity. From the assay, it was determined that compound II exhibited 7.9 nM towards CK1δ. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Product Details of 908267-63-0

The Article related to heteroaromatic preparation casein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 15, 2018, Chen, Xuxing; Geng, Meiyu; Jiang, Lei; Chen, Yi; Cao, Jianhua; Jiang, Qingyun; Shen, Qianqian; Ding, Jian; Yao, Yucai; Zhao, Zhao; Xiong, Yuanfang published a patent.Safety of 4-Bromo-2-isopropylpyridine The title of the patent was Pyrido five-element aromatic ring compound, preparation method therefor and use thereof. And the patent contained the following:

The present invention provides a pyrido five-element aromatic ring compound (e.g., I), and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Safety of 4-Bromo-2-isopropylpyridine

The Article related to pyridoarom ezh inhibitor antitumor autoimmune preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 4-Bromo-2-isopropylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 1, 2020, Zhou, Xiaocong; He, Xinyi; Yan, Puzha; Li, Yuanqiang published a patent.Recommanded Product: 908267-63-0 The title of the patent was Trifluoromethylation of dimethyl substituted heterocyclic compounds. And the patent contained the following:

The invention relates to the trifluoromethylation of di-Me substituted heterocyclic compounds, and has the advantage of wide range of substrate selection. For example, 2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridine was prepared by trifluoromethylation of 2-isopropyridine and 5-(trifluoromethyl)-5H-dibenzo[b,d]thiophen-5-ium trifluoromethanesulfonate. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Recommanded Product: 908267-63-0

The Article related to trifluoromethylation preparation pyrimidine quinoxaline quinazoline pyrazine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 11, 2014, Van Gool, Michiel Luc Maria; Alonso-De Diego, Sergio-Alvar; Cid-Nunez, Jose Maria; Delgado-Gonzalez, Oscar; Decorte, Annelies Marie Antonius; Macdonald, Gregor James; Megens, Antonius Adrianus Hendrikus Petrus; Trabanco-Suarez, Andres Avelino; Garcia-Molina, Aranzazu; Andres-Gil, Jose Ignacio published a patent.Category: pyridine-derivatives The title of the patent was Preparation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mGluR2 receptors. And the patent contained the following:

Title compounds I [R1 = substituted Ph or 2-pyridinyl; R2 = substituted pyridinyl; R3 = H or alkyl; R4 = H, alkyl, mono- or polyhalo-alkyl, alkyl-O-alkyl or alkyl-OH], or a N-oxide, or a pharmaceutically acceptable salt or a solvate, are prepared as neg. allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (mGluR2). Thus, e.g., II was prepared by reaction of (7S)-methyl-3-(2-methylpyridin-4-yl)-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazin-4-one with 4-bromobenzotrifluoride. Compound II showed pIC50 value of 8.05 against hmGluR2 in GTPγS binding assay. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved, especially CNS disorders. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Category: pyridine-derivatives

The Article related to dihydropyrazolopyrazine preparation neg allosteric mglur2 receptors cns disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 5, 2004, Kwan, Tricia Ann; Lagreca, Susan Deborah; Lippa, Blaise Scott; Morris, Joel; Wessel, Matthew David published a patent.Formula: C8H10BrN The title of the patent was Preparation of isothiazole derivatives as anticancer agents. And the patent contained the following:

The title compounds I [X = O or S; R1 = (substituted)heterocyclic aromatic ring; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, etc.] were prepared Compounds I are useful as as anticancer agents (no data). Thus, reaction of 3-methanesulfonyl-5-(pyridin-4-ylamino)-isothiazole-4-carboxylic acid amide (preparation given) with (4-chlorophenyl)-methanethiol yielded compound II. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Formula: C8H10BrN

The Article related to isothiazole derivative preparation anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Formula: C8H10BrN

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem